CD8+ T-cell receptor recognizing influenza peptide–MHC class I complexes (TCR-pMHC (Influenza))

CD8+ T-cell receptors (TCRs) recognizing influenza peptide–MHC class I complexes are pivotal for the adaptive immune system's ability to clear influenza virus infections. These receptors, expressed on cytotoxic T lymphocytes, recognize specific viral peptides—such as the highly conserved M1(58-66) epitope—presented by Major Histocompatibility Complex (MHC) class I molecules (PubMed: 28439028). Upon recognition, the TCR triggers a signaling cascade that results in the targeted destruction of infected cells and the production of pro-inflammatory cytokines (UniProt: P01850). This specific interaction is a major focus for the development of universal influenza vaccines and adoptive TCR-T cell therapies, which aim to provide broad-spectrum protection against diverse viral strains (PubMed: 30635454). From a therapeutic perspective, the stability and affinity of the TCR-pMHC bond are critical for ensuring potent immune activation while avoiding off-target effects. However, the high mutation rate of influenza viruses and the diversity of human HLA alleles present significant challenges for the widespread application of TCR-based interventions (PubMed: 25148024).

Other names

Influenza-specific T-cell receptorCD8+ TCR-influenza pMHC complexFlu-specific TCRM1-specific TCRTCR-pMHC complex

The TCR specifically recognizes and binds to influenza-derived peptides presented by MHC class I molecules on the surface of infected cells. This binding event triggers a signaling cascade through the CD3 complex, leading to T-cell activation, proliferation, and the release of cytotoxic molecules like perforin and granzymes, as well as antiviral cytokines such as IFN-gamma, to eliminate the virus-infected cells.